BioNTech's mRNA cancer therapy misses first goal in head and neck trial | Reuters

BioNTech's mRNA cancer therapy fails primary endpoint in head and neck trial

BioNTech announced its investigational mRNA cancer treatment did not meet the primary endpoint in a late-stage trial for head and neck cancer, marking a setback for the company's oncology pipeline.